Safety and efficacy of tocilizumab in COVID-19: A systematic evaluation of adverse effects and therapeutic outcomes
This study confirms tocilizumab's position as a valuable therapeutic agent for COVID-19 complications while highlighting the necessity for judicious patient selection and vigilant monitoring due to its potential for significant adverse effects. The findings underscore the importance of pre-treatment screening, adherence to contraindications, and ongoing pharmacovigilance to optimize risk-benefit ratios.
Authors
- Tafadzwa Dzinamarira (ORCID: https://orcid.org/0000-0002-9929-5739)
- Ahmad Alhowail (ORCID: https://orcid.org/0000-0003-1427-032X)
- Syed Mohammed Basheeruddin Asdaq (ORCID: https://orcid.org/0000-0003-1533-9667)
- Abida Khan (ORCID: https://orcid.org/0000-0001-5261-4010)
- Syed Imam Rabbani (ORCID: https://orcid.org/0000-0001-6344-1071)
- Othman AlOmeir (ORCID: https://orcid.org/0000-0002-3800-6825)
- Mohd Imran (ORCID: https://orcid.org/0000-0002-6064-1040)
- Rafiulla Gilkaramenthi
Institutions
- Northern Border University (SA)
- Alfaisal University (SA)
- Qassim University (SA)
- Shaqra University (SA)
- Buraydah Colleges (SA)
- University of Pretoria (ZA)
Publication Details
- Journal
- Journal of Infection and Public Health
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1016/j.jiph.2025.102873
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.40